• HRS-1596 is a phase I-ready GLP-1/GIP dual receptor agonist for once-weekly oral dosing          
• Total potential deal value is up to 2.6 billion US dollars, including 300 million dollars upfront, as well as potential sales royalties

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.